Research programme: antimicrobial therapeutics - AUM LifeTech
Latest Information Update: 13 Apr 2023
At a glance
- Originator AUM LifeTech
- Developer AUM LifeTech; UT Southwestern
- Class Antibacterials; Antifungals; Antisense oligonucleotides; Antivirals
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 13 Apr 2023 Discontinued for Infections in USA (Parenteral) (AUM LifeTech pipeline; April 2023)
- 19 Feb 2021 Antimicrobial therapeutics is available for licensing as of 19 Feb 2021. https://aumlifetech.com/alliances/